Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 8.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 34(25):3107-3108.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 34(7):731-739.

Wick, W; Weller, M; van den Bent, M; Sanson, M; Weiler, M; von Deimling, A; Plass, C; Hegi, M; Platten, M; Reifenberger, G (2014). MGMT testing-the challenges for biomarker-based glioma treatment. Nature Reviews. Neurology, 10(7):372-85.

Tabatabai, G; Hegi, M; Stupp, R; Weller, M (2012). Clinical implications of molecular neuropathology and biomarkers for malignant glioma. Current Neurology and Neuroscience Reports, 12(3):302-307.

Weller, M; Stupp, R; Hegi, M; Wick, W (2012). Individualized targeted therapy for glioblastoma: fact or fiction? Cancer Journal, 18(1):40-44.

Preusser, M; de Ribaupierre, S; Wöhrer, A; Erridge, S C; Hegi, M; Weller, M; Stupp, R (2011). Current concepts and management of glioblastoma. Annals of Neurology, 70(1):9-21.

Faoro, D; von Bueren, A O; Shalaby, T; Sciuscio, D; Hürlimann, M L; Arnold, L; Gerber, N U; Haybaeck, J; Mittelbronn, M; Rutkowski, S; Hegi, M; Grotzer, M A (2011). Expression of O(6)-methylguanine-DNA methyltransferase in childhood medulloblastoma. Journal of Neuro-Oncology, 103(1):59-69.

Stupp, R; Hegi, M; Weller, M (2010). Neuro-oncology, a decade of temozolomide and beyond. Expert Review of Anticancer Therapy, 10(11):1675-1677.

This list was generated on Sat Nov 18 05:35:15 2017 CET.